688298 Zhejiang Orient Gene BiotechWatchlist
Zhejiang Orient Gene Biotech News
Oriental Biology (688298.SH): Controlling shareholders Anji Fulanglai and Fangshi Holdings voluntarily promise not to reduce their holdings of the company's shares within 18 months
On December 6, Gelonghui (688298.SH) announced that based on confidence in the company's future development prospects and recognition of the company's values, and at the same time, to support the company's continuous, healthy and stable development and reasonable reflection of internal value, the interests of investors are protected. Anji Fulanglai, the controlling shareholders of Oriental Biotech, and Fangshi Holdings voluntarily promised: “Within 18 months from now (that is, December 6, 2023 to June 5, 2025), we will not reduce our holdings of Oriental Biotech's shares directly held by the Company in any way, including the transfer of shares directly held by the Company during the commitment period due to capital accumulation, distribution of stock dividends, stock allocations,
A Look At The Intrinsic Value Of Zhejiang Orient Gene Biotech Co.,Ltd (SHSE:688298)
Key Insights Zhejiang Orient Gene BiotechLtd's estimated fair value is CN¥34.32 based on Dividend Discount Model Current share price of CN¥40.15 suggests Zhejiang Orient Gene BiotechLtd is potential
Oriental Biology (688298.SH): Alzheimer's disease-related testing products are in the development stage
Gelonghui, November 27|Oriental Biology (688298.SH) said on an interactive platform that the company and its subsidiary's Mycoplasma pneumoniae POCT rapid detection reagent and nucleic acid detection reagent have obtained EU CE certification. The subsidiary's Mycoplasma pneumoniae POCT rapid test reagent holds three types of domestic medical device certificates. For details, see the regular reports disclosed by the company over the years; the company's Alzheimer's disease-related testing products are in the development stage.
Oriental Biology (688298.SH): Net loss of 72.384 million yuan in the first three quarters
On October 30, Gelonghui (688298.SH) released its report for the third quarter of 2023. The company achieved operating income of 652 million yuan in the first three quarters, a decrease of 91.70% over the previous year; net loss attributable to shareholders of listed companies of 72.384 million yuan; and net loss attributable to shareholders of listed companies to deduct non-recurring profits and losses of 105 million yuan.
Health Check: How Prudently Does Zhejiang Orient Gene Biotech (SHSE:688298) Use Debt?
The external fund manager backed by Berkshire Hathaway's Charlie Munger, Li Lu, makes no bones about it when he says 'The biggest investment risk is not the volatility of prices, but whether you will
[Instant Analysis of BT Financial Report] Oriental Biotech 2023 Interim Report Analysis: Facing challenges, responding positively, business conditions to be seen
Oriental Biology (stock code: 688298) is a company focusing on the in vitro diagnosis industry. Its industry is the in vitro diagnosis industry under the medical device industry. In vitro diagnostic products mainly include diagnostic equipment and diagnostic reagents, among which diagnostic reagents dominate the entire industry. The size of the global in vitro diagnostic market continues to grow, and is expected to grow at a compound annual growth rate of around 6% in the future. As a member of the in vitro diagnostic industry, Dongfang Biotech is expected to benefit from the development trend of the industry. However, according to Dongfang Biotech's 2023 interim report, the company faced a sales business that basically removed COVID-19 testing products during this reporting period, resulting in
A Look At The Fair Value Of Zhejiang Orient Gene Biotech Co., Ltd. (SHSE:688298)
Key Insights The projected fair value for Zhejiang Orient Gene Biotech is CN¥34.32 based on Dividend Discount Model Current share price of CN¥37.44 suggests Zhejiang Orient Gene Biotech is potential
Does Zhejiang Orient Gene Biotech (SHSE:688298) Have A Healthy Balance Sheet?
Howard Marks put it nicely when he said that, rather than worrying about share price volatility, 'The possibility of permanent loss is the risk I worry about... and every practical investor I know wor
Oriental Biology: Launching a New Etoromide Urine Test Kit
GLONGHUI July 17丨Dongfang Biotech News. Recently, in response to the new “top” e-cigarette, Oriental Biotech launched a new product that relies on the tonomide urine test kit (colloidal gold method), which can more accurately crack down on drug addicts that rely on tolimide, help anti-drug workers carry out their work better, and curb the risk of etomide abuse.
Orient Gene Biotech Registers New In Vitro Diagnostic Reagents
Zhejiang Orient Gene Biotech (SHA:688298) obtained a registration certificate for its new in vitro diagnostic reagents, according to a filing on Thursday. The Chinese vitro diagnostic products maker's
Oriental Biology (688298.SH): Obtaining a medical device registration certificate
On July 12, GLONGHUI | Oriental Biology (688298.SH) announced that the company recently obtained domestic medical device registration certificates (in vitro diagnostic reagents) for the following products. Product name: cancer embryo antigen, neuron-specific enolase, and cytokeratin 19-segment test kit (flow fluorescence luminescence method). This product is used to quantitatively detect the content of cancer embryo antigen (CEA), neuron-specific enolase (NSE), and cytokeratin 19 fragment (CYFRA21-1) in human serum in vitro. It is mainly used for dynamic monitoring of patients with malignant tumors to help determine disease progression or treatment effects, no
Oriental Biotech (688298.SH) and related responsible personnel received a warning letter from the Zhejiang Securities Regulatory Bureau
Zhitong Finance App News, Oriental Biology (688298.SH) announced that on July 5, 2023, the company received the “Decision on Issuing Warning Letter Measures against Zhejiang Oriental Gene Biological Products Co., Ltd. and Related Responsible Personnel” from the Zhejiang Regulatory Bureau of the China Securities Regulatory Commission. The decision stated that on February 28, 2023, the company disclosed the “2022 Annual Results Report Notice” and expects to achieve net profit attributable to shareholders of listed companies of 298,0207 million yuan in 2022. On April 26, 2023, the company disclosed the “2022 Annual Performance Report Corrections
Company Q&A 丨 Dongfang Biotech: Currently, the company does not have any brain-computer interface, innovative drug research and development and other related businesses
Gelonghui, June 21丨An investor asked Dongfang Biotech Company a question on the interactive platform: Does your company have strong R&D capabilities, strong technical strength, and brain-computer interface-related business or R&D? Does the company develop gene sequencing technology? Innovative drug development team? Dongfang Biotech responded: Currently, the company does not have any brain-computer interface, innovative drug research and development and other related businesses. The company's molecular diagnostic platform covers the development of gene sequencing technology.
Three products of Dongfang Biotech (688298.SH) have obtained overseas certification
Zhitong Finance App, Dongfang Biotech (688298.SH) announced that the company has recently obtained overseas certifications for the following major products. The product names are Healgen URS Test Strip Urinary Tract Infection Test Strip, COVID-19/Flu A&B A&B Ag Combo Rapid Test Cassette (Swab) COVID/A & B Antigen Joint Test Reagent (colloidal gold method) and COVID-19/Flu A&B/RSV/Adeno Ag Combo rap
Forty-three shares are about to be distributed, and Shanxi Fenjiu is currently the biggest party
Gelonghui, June 21丨According to the Securities Times, statistics show that there are 43 listed companies whose equity registration date is today (June 21). Judging from the dividend plans of these companies, there are 36 companies that distribute cash amounts of 1 yuan (tax included) or more for every 10 shares. Among them, Shanxi Fenjiu disbursed the largest amount, disbursing 33.2 yuan for every 10 shares; Dongfang Biotech and Western Superconductor followed, with cash disbursements of 20 yuan and 10 yuan for every 10 shares, respectively. Judging from the transfer ratio, the equity registration date is today. Of the companies that are about to implement dividends, there are 3 transfer companies with a high percentage of transfer shares of 5 shares or more for every 10 shares. Zhaomin Technology and Yibo
Dongfang Biotech (688298.SH) plans to distribute 2 yuan per share in 2022 to transfer 0.2 shares, excluding interest on June 26
According to the Zhitong Finance App, Dongfang Biotech (688298.SH) announced that the profit distribution and share capital transfer was based on the company's total share capital before implementation of the plan. A cash dividend of 2 yuan (tax included) was distributed per share, and the capital reserve fund was used to transfer 0.2 shares per share to all shareholders. The deduction (interest) date for this distribution of equity is 2023/6/26.
Zhejiang Orient Gene Biotech Elects Chairman, Vice Chairman
Zhejiang Orient Gene Biotech (SHA:688298) has elected Fang Jianqiu as the company's new chairman, according to a filing on Thursday. Fang was elected alongside Bing Liang, who was named vice chairman
Zhejiang Orient Gene Biotech (SHSE:688298) Adds CN¥408m to Market Cap in the Past 7 Days, Though Investors From a Year Ago Are Still Down 52%
The nature of investing is that you win some, and you lose some. Anyone who held Zhejiang Orient Gene Biotech Co., Ltd. (SHSE:688298) over the last year knows what a loser feels like. To wit the sha
Dongfang Biotech (688298.SH): Guo Xingzhong, a core technician, leaves
According to the Zhitong Finance App, Dongfang Biotech (688298.SH) announced that Guo Xingzhong, the company's core technician, recently applied for personal reasons to resign from the subsidiary Hangzhou Danwei Biotechnology Co., Ltd. (“Hangzhou Danwei” or “subsidiary”) and has gone through separation procedures. After Guo Xingzhong leaves his job, the company will hire him as the company's technical consultant. According to reports, Guo Xingzhong was mainly responsible for the development and industrialization of molecular diagnostic reagents during his tenure at the subsidiary Hangzhou Danwei.
Dongfang Biotech (688298.SH): Elected Fang Jianqiu as Chairman
Gelonghui, May 31 丨 Dongfang Biotech (688298.SH) announced that the members of the company's third board of directors have been elected at the 2022 Annual General Meeting of Shareholders. According to the “Company Law”, “Articles of Association” and other relevant regulations, the meeting elected Fang Jianqiu as the chairman of the third board of directors of the company and Fang Bingliang as the vice chairman of the third board of directors of the company. Their terms of office began on the date of review and approval by the current board of directors until the end of the term of the third board of directors.